Real-World Analysis Compares Inpatient and Outpatient CAR T-Cell Therapy in MCL and Follicular Lymphoma
Inpatient infusion was linked with greater comorbidity burden and increased likelihood of adverse effects in patients with follicular lymphoma who received CAR T-cell therapy, but not in those with mantle cell lymphoma.
Siltuximab May Be Effective Treatment for CRS/ICANS Following CAR T-Cell Therapy
Siltuximab led to the complete resolution of cytokine release syndrome in 5 out of 6 patients, with a median time to complete response within 1 hour.
Nurse Researchers Make The Case For “Real-Time Toxicity” Teams in Bone Marrow Transplantation
Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.
Educational Interventions Prove Beneficial for Caregivers of Pediatric Patients Receiving HSCT
Nurse researchers sought to improve the communication between the hematopoietic stem cell transplantation care team and pediatric patient caregivers.
Remote Patient Monitoring for CAR T Demonstrates Feasibility in the Outpatient Setting
During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.
Moving CAR T-Cell Treatment to Outpatient Setting: A Real-World Case Study
At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program.
Essential Oils May Provide Relief from Chemotherapy-Induced Nausea and Vomiting
Pure essential oils reduced the severity of chemotherapy-induced nausea and vomiting in patients receiving autologous blood and marrow transplants.
Oncology Nurses Drastically Reduce Central Line Infection Incidences Through Peer-to-Peer Observation Strategy
Oncology nurses at the 2022 ASTCT Meeting shared how a peer-to-peer observation and validation tool helped decrease central line-associated bloodstream infections by 68%.
Liso-cel Exhibits Durable Responses in Relapsed-Refractory Large B-Cell Lymphoma
Patients with relapsed/refractory large B-cell lymphoma continued to derive benefit from lisocabtagene maraleucel after 2 years of follow-up.
Axi-cel Sustains Long-Term Survival Rates in Relapsed/Refractory Large B-Cell Lymphoma
Patients with relapsed or refractory large B-cell lymphoma experienced improved overall survival following treatment with axicabtagene ciloleucel.
Belimumab May Help Prevent Chronic GVHD in Adults Undergoing Allogenic Transplant
Belimumab has emerged as a safe and tolerable agent that may be useful for the prophylaxis of chronic graft-vs-host-disease.
Ruxolitinib Is Promising in Pediatric Chronic GVHD
Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
